« Return to News | Drug Sponsors

Lupin signs $58M licensing pact

Monday, July 25, 2011 01:56 PM

Indian drug maker Lupin has signed a pact with U.S.-based Medicis Pharmaceutical to develop multiple therapeutic compounds using Lupin's formulation technologies.

Lupin would receive an up front payment of $20 million from Medicis in addition to various milestone payments of up to $38 million, according to Reuters.

Medicis would have global exclusive rights for the products developed under the agreement. Lupin would receive single digit royalty on sales achieved by Medicis and hold marketing rights in India, it said.

"This partnership is a fairly long-term one and the products to be developed are from a variety of segments although Medicis primarily works in dermatology sector," Nilesh Gupta, group president and executive director of Lupin told Reuters. The development would further help Lupin build a strong specialty business, he said.

Lupin's U.S. unit has settled the litigation over Solodyn extended release tablets with Medicis, the Indian firm said. The settlement allows Lupin to sell the generic version of Solodyn, a drug used to treat pimples and red bumps, commencing November this year or earlier under certain conditions in the U.S.  The settlement also lets Lupin sell the same drug with different strengths from 2018 and 2019 onwards.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.